Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Bug fixes #102

Merged
merged 4 commits into from
Jan 15, 2024
Merged

Bug fixes #102

Show file tree
Hide file tree
Changes from all commits
Commits
Show all changes
4 commits
Select commit Hold shift + click to select a range
4686996
Adds Carbamazepine-Midazolam-DDI data reported by Kanefendt et al. 2023
AndreDlm Jan 11, 2024
361d15b
Removes empty lines in csv file
AndreDlm Jan 11, 2024
9ae8793
Merge branch 'Open-Systems-Pharmacology:master' into master
AndreDlm Jan 15, 2024
a75474e
Some bug fixes
AndreDlm Jan 15, 2024
File filter

Filter by extension

Filter by extension
Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
18 changes: 9 additions & 9 deletions DDI.csv
View file
Open in desktop
Original file line number Diff line number Diff line change
Expand Up @@ -314,17 +314,17 @@
16249,Härtter 2012 RIF,https://pubmed.ncbi.nlm.nih.gov/22348256/,Dabigatran + Rifampicin Day 9,Dabigatran,Rifampicin,PO,PO,Induction,Plasma,0.33,GMR,,,0.345,GMR,,,0,inf,156,324,h,1,,600,,mg,PO,"(S-0,T-24,R-7)",h,OD (7 days),OD,,,,,,fasted,,,
16250,Härtter 2012 RIF,https://pubmed.ncbi.nlm.nih.gov/22348256/,Dabigatran + Rifampicin Day 16,Dabigatran,Rifampicin,PO,PO,Induction,Plasma,0.823,GMR,,,0.814,GMR,,,0,inf,324,492,h,1,,600,,mg,PO,"(S-0,T-24,R-7)",h,OD (7 days),OD,,,,,,fasted,,,
16251,Härtter 2012 RIF,https://pubmed.ncbi.nlm.nih.gov/22348256/,Dabigatran + Rifampicin Day 23,Dabigatran,Rifampicin,PO,PO,Induction,Plasma,0.857,GMR,,,0.816,GMR,,,0,inf,492,526,h,1,,600,,mg,PO,"(S-0,T-24,R-7)",h,OD (7 days),OD,,,,,,fasted,,,
16253,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 10 mg Rifampicin,total Dabigatran,Rifampicin,PO,PO,Induction,Plasma,0.594,GMR,0.460-0.768,90% CI,0.568,GMR,0.423-0.762,90% CI,0,inf,228,660,h,1,,10,,mg,PO,S0-T24-R18,h,OD,,,,,,,fasted,,,
16254,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 75 mg Rifampicin,total Dabigatran,Rifampicin,PO,PO,Induction,Plasma,0.38,GMR,0.304-0.475,90% CI,0.384,GMR,0.308-0.479,90% CI,0,inf,660,inf,h,1,,"first 10, then 75",,mg,PO,"S0-T24-R18 (10 mg), S432-T24-R18 (75 mg)",h,OD,,,,,,,fasted,,,
16256,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 2 mg Rifampicin,total Dabigatran,Rifampicin,PO,PO,Induction,Plasma,1.19,GMR,0.93-1.53,90% CI,1.07,GMR,0.82-1.40,90% CI,0,inf,228,660,h,1,,2,,mg,PO,S0-T24-R18,h,OD,,,,,,,fasted,,,
16257,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 600 mg RIfampicin,total Dabigatran,Rifampicin,PO,PO,Induction,Plasma,0.334,GMR,0.269-0.413,90% CI,0.305,GMR,0.241-0.385,90% CI,0,inf,660,inf,h,1,,"first 2, then 600",,mg,PO,"S0-T24-R18 (2 mg), S432-T24-R18 (600 mg)",h,OD,,,,,,,fasted,,,
16253,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 10 mg Rifampicin,Dabigatran total,Rifampicin,PO,PO,Induction,Plasma,0.594,GMR,0.460-0.768,90% CI,0.568,GMR,0.423-0.762,90% CI,0,inf,228,660,h,1,,10,,mg,PO,S0-T24-R18,h,OD,,,,,,,fasted,,,
16254,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 75 mg Rifampicin,Dabigatran total,Rifampicin,PO,PO,Induction,Plasma,0.38,GMR,0.304-0.475,90% CI,0.384,GMR,0.308-0.479,90% CI,0,inf,660,inf,h,1,,"first 10, then 75",,mg,PO,"S0-T24-R18 (10 mg), S432-T24-R18 (75 mg)",h,OD,,,,,,,fasted,,,
16256,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 2 mg Rifampicin,Dabigatran total,Rifampicin,PO,PO,Induction,Plasma,1.19,GMR,0.93-1.53,90% CI,1.07,GMR,0.82-1.40,90% CI,0,inf,228,660,h,1,,2,,mg,PO,S0-T24-R18,h,OD,,,,,,,fasted,,,
16257,Lutz 2018a,https://pubmed.ncbi.nlm.nih.gov/29569723/,Dabigatran + 600 mg RIfampicin,Dabigatran total,Rifampicin,PO,PO,Induction,Plasma,0.334,GMR,0.269-0.413,90% CI,0.305,GMR,0.241-0.385,90% CI,0,inf,660,inf,h,1,,"first 2, then 600",,mg,PO,"S0-T24-R18 (2 mg), S432-T24-R18 (600 mg)",h,OD,,,,,,,fasted,,,
16259,Rattanacheeworn 2021,https://pubmed.ncbi.nlm.nih.gov/34603040/,Dabigatran + 450 mg RIfampicin,Dabigatran,Rifampicin,PO,PO,Induction,Plasma,2.22,GMR,1.74-2.83,95% CI,1.86,GMR,1.43-2.43,95% CI,0,inf,0,inf,h,1,,450,,mg,PO,1,h,SD,,,,,,,fasted,,,
16261,Tatosian 2020,https://pubmed.ncbi.nlm.nih.gov/32705692/,Dabigatran + 600 mg RIfampicin,Dabigatran,Rifampicin,PO,PO,Induction,Plasma,2.08,GMR,1.66-2.60,95% CI,1.92,GMR,1.47-2.43,95% CI,0,inf,0,inf,h,1,,600,,mg,PO,1,h,SD,,,,,,,fasted,,,
16263,Härtter 2012 Vera,https://pubmed.ncbi.nlm.nih.gov/22348256/,"Vera 120mg BID, Dabigatran 1h after (Treatment C)",total Dabigatran,Verapamil,PO,PO,mechanism-based inactivation,Plasma,1.54,GMR,1.19-1.99,90% CI,1.63,GMR,1.22-2.17,90% CI,0,inf,73,166,h,1,,120,,mg,PO,"(S-0,T-12,R-14)",h,BID (7 days),,,,,,,fasted,,,
16264,Härtter 2012 Vera,https://pubmed.ncbi.nlm.nih.gov/22348256/,"Vera 120mg BID, Dabigatran 2h before (Treatment D)",total Dabigatran,Verapamil,PO,PO,mechanism-based inactivation,Plasma,1.18,GMR,0.91-1.52,90% CI,1.12,GMR,0.84-1.49,90% CI,0,inf,166,265,h,1,,120,,mg,PO,"(S-0,T-12,R-16)",h,BID (8 days),,,,,,,fasted,,,
16265,Härtter 2012 Vera,https://pubmed.ncbi.nlm.nih.gov/22348256/,"Vera 120mg TID/QID, Dabigatran 1h after (Treatment E)",total Dabigatran,Verapamil,PO,PO,mechanism-based inactivation,Plasma,1.39,GMR,1.07-1.81,90% CI,1.34,GMR,1.00-1.80,90% CI,0,inf,265,336,h,1,,120,,mg,PO,"(S-0,T-12,R-16), (S-192,T-8,R-3), (S-216,T-6,R-12)",h,"BID (8 days), TID (1 day), QID (3 days)",,,,,,,fasted,,,
16263,Härtter 2012 Vera,https://pubmed.ncbi.nlm.nih.gov/22348256/,"Vera 120mg BID, Dabigatran 1h after (Treatment C)",Dabigatran total,Verapamil,PO,PO,mechanism-based inactivation,Plasma,1.54,GMR,1.19-1.99,90% CI,1.63,GMR,1.22-2.17,90% CI,0,inf,73,166,h,1,,120,,mg,PO,"(S-0,T-12,R-14)",h,BID (7 days),,,,,,,fasted,,,
16264,Härtter 2012 Vera,https://pubmed.ncbi.nlm.nih.gov/22348256/,"Vera 120mg BID, Dabigatran 2h before (Treatment D)",Dabigatran total,Verapamil,PO,PO,mechanism-based inactivation,Plasma,1.18,GMR,0.91-1.52,90% CI,1.12,GMR,0.84-1.49,90% CI,0,inf,166,265,h,1,,120,,mg,PO,"(S-0,T-12,R-16)",h,BID (8 days),,,,,,,fasted,,,
16265,Härtter 2012 Vera,https://pubmed.ncbi.nlm.nih.gov/22348256/,"Vera 120mg TID/QID, Dabigatran 1h after (Treatment E)",Dabigatran total,Verapamil,PO,PO,mechanism-based inactivation,Plasma,1.39,GMR,1.07-1.81,90% CI,1.34,GMR,1.00-1.80,90% CI,0,inf,265,336,h,1,,120,,mg,PO,"(S-0,T-12,R-16), (S-192,T-8,R-3), (S-216,T-6,R-12)",h,"BID (8 days), TID (1 day), QID (3 days)",,,,,,,fasted,,,
16228,Delavenne 2013,https://pubmed.ncbi.nlm.nih.gov/23210726/,Subject 10 Clarithromycin treatment,Dabigatran,Clarihromycin,PO,PO,mechanism-based inactivation,Plasma,1.491,GMR,,,1.602,GMR,,,0,inf,70.5,144,h,1,,500,,mg,PO,"(S-0,T-12,R-6), 70.5",h,BID (3.5 days),,,,,,,fasted,,,
16266,Lutz 2018b,https://pubmed.ncbi.nlm.nih.gov/29569712/,Dabigatran control,total Dabigatran,Carbamazepine,PO,PO,Induction,Plasma,0.714,GMR,0.593-0.859,90% CI,0.666,GMR,0.521-0.852,90% CI,0,inf,404,480,h,1,,300,,mg,PO,"(S-0,T-12,R-52)",h,BID (26 days),,,,,,,fasted,,,
16266,Lutz 2018b,https://pubmed.ncbi.nlm.nih.gov/29569712/,Dabigatran control,Dabigatran total,Carbamazepine,PO,PO,Induction,Plasma,0.714,GMR,0.593-0.859,90% CI,0.666,GMR,0.521-0.852,90% CI,0,inf,404,480,h,1,,300,,mg,PO,"(S-0,T-12,R-52)",h,BID (26 days),,,,,,,fasted,,,
16301,Wiebe 2020,https://pubmed.ncbi.nlm.nih.gov/32504272/,Digoxin (Cocktail) + Rifampin,Digoxin,Rifampicin,PO,PO,induction,Plasma,1.31,Geom. Mean,0.18,gCV,218.26,Geom. Mean,27.7,gCV,0,inf,312,inf,h,,,600,,mg,PO,S0-R1,h,SD,,tablet,"(Eremfat® 600 mg; Riemser Pharma GmbH, Greifswald–Insel Riems, Germany",,280,,Fasted,overnight,,
16302,Wiebe 2020,https://pubmed.ncbi.nlm.nih.gov/32504272/,Digoxin (Cocktail) + Rifampin,Digoxin,Rifampicin,PO,PO,induction,Urine,1.11,Geom. Mean,,,,,,,,,,,h,,1/CLR,600,,mg,PO,S0-R1,h,SD,,tablet,"(Eremfat® 600 mg; Riemser Pharma GmbH, Greifswald–Insel Riems, Germany",,280,,Fasted,overnight,,
16305,Kurata 2002,https://pubmed.ncbi.nlm.nih.gov/12189368/,G/G2677C/C3435_Digoxin day 16 + Clarithromycin,Digoxin,Clarithromycin,PO,PO,Reversible_Inhibition,serum,0.743,Approx. Avg,,,1.025,Approx. Avg,,,0,inf,120,inf,h,0.5,,400,,mg,PO,S0-T12-R16,h,MD,,,,,,,,,,
Expand Down Expand Up @@ -429,4 +429,4 @@
16785,Tatosian 2020,https://pubmed.ncbi.nlm.nih.gov/32705692/,PO Rosuvastatin 50 ug control,Rosuvastatin,Rifampicin,PO,PO,Reversible_Inhibition,Plasma,3.56,GMR,,,10.94,GMR,,,0,inf,72,inf,h,,Single Dose study,,,,,,,,,,,,,,,,,
16602,Stangier 2009,https://pubmed.ncbi.nlm.nih.gov/19178132/,Dabigatran + Atorvastatin,Dabigatran total,Atorvastatin,PO,PO,,Plasma,0.862,Approx. Avg,,,0.847,Approx. Avg,,,72,inf,72,inf,h,,,80,,mg,PO,S0-T24-R4,h,,,Tablet,,,,Sortis ® ,fasted,overnight,,
943,Kanefendt 2023,https://pubmed.ncbi.nlm.nih.gov/38105467/,"Study 1, midazolam after pretreatment with carbamazepine",Midazolam,Carbamazepine,PO,PO,Induction,Plasma,0.282,GMR,"0.235, 0.340",95% confidence interval,0.44,GMR,"0.374, 0.518",95% confidence interval,0,inf,334,inf,h,,,,,,,,,,,,,,,,,,,
1133,Kanefendt 2023,https://pubmed.ncbi.nlm.nih.gov/38105467/,"Study 2, midazolam after pretreatment with carbamazepine",Midazolam,Carbamazepine,PO,PO,Induction,Plasma,0.323,GMR,"0.256, 0.407",95% confidence interval,0.455,GMR,"0.375, 0.552",95% confidence interval,0,inf,336,inf,h,,,,,,,,,,,,,,,,,,,
1133,Kanefendt 2023,https://pubmed.ncbi.nlm.nih.gov/38105467/,"Study 2, midazolam after pretreatment with carbamazepine",Midazolam,Carbamazepine,PO,PO,Induction,Plasma,0.323,GMR,"0.256, 0.407",95% confidence interval,0.455,GMR,"0.375, 0.552",95% confidence interval,0,inf,336,inf,h,,,,,,,,,,,,,,,,,,,
Binary file modified ObsDataPK_OSP.xlsx
View file
Open in desktop
Binary file not shown.
Loading